Results

Total Results: 425 records

Showing results for "laboratory".

401. Type-2-Diabetes-Medications-Update Surveillance (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/type-2-diabetes-medications-update_surveillance.pdf
     December 31, 2013 - RCT 44 patients on a stable dosage of metformin 12 weeks Change in HbA1, vascular effects (laboratory

402. FRN 29: Future Research Needs on Procalcitonin-Guided Antibiotic Therapy (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/procalcitonin-future_research.pdf
     August 01, 2014 - A laboratory perspective is essential in planning studies.

403. Cannabis-2022-Update-Surv-Rep-1-App-F1-4 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2022-update-surv-rep-1-app-F1-4.xlsx
     January 01, 2022 - to nabilone 250 ug titrated up to a max of 2 mg/day Max dose 240 mg/day NA NA NA NA 6 Short Other (laboratory

404. Cer-250-Cannabis-Tables-E1-E4-2022-Update 0 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-tables-e1-e4-2022-update_0.xlsx
     January 01, 2022 - to nabilone 250 ug titrated up to a max of 2 mg/day Max dose 240 mg/day NA NA NA NA 6 Short Other (laboratory

405. Disposition of Comments Report for Pressure Ulcer Risk Assessment and Prevention (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/pressure-ulcer-prevention_disposition-comments.pdf
     May 08, 2013 - not only anthropomorphic measures of nutritional status such as BMI or recent weight loss but also laboratory-based

406. Future Research Needs for Treatment of Obstructive Sleep Apnea (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/sleep-apnea-treatment-future_research.pdf
     February 01, 2012 - However, these trials have used sleepiness and laboratory indicators like sleepiness scores and AHI

407. Cannabis-2022-Surv-Rep-3-Tables-F1-4 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2022-surv-rep-3-tables-F1-4.xlsx
     January 01, 2022 - to nabilone 250 ug titrated up to a max of 2 mg/day Max dose 240 mg/day NA NA NA NA 6 Short Other (laboratory

408. Infectious Disease Including HIV/AIDS #09 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/infectious-disease-horizon-scan-high-impact-1512.pdf
     January 28, 2016 - The rVSV-ZEBOV vaccine was developed by the Public Health Agency of Canada’s National Microbiology Laboratory

409. Public-Reporting-Cost-Measures Technical-Brief (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/public-reporting-cost-measures_technical-brief.pdf
     March 01, 2015 - care settings, the vendors report on costs for medical treatments, procedures, imaging tests, and laboratory

410. Template for Draft Reports (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cad-pci-bypass_appendixes.pdf
     October 06, 2006 - ο Yes ο No ο Not stated Describe the method of interpretation of angiograms. ο Central Laboratory

411. Cannabis-2023-Surv-Rep-1-App-F (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2023-surv-rep-1-app-F.xlsx
     January 01, 2023 - to nabilone 250 ug titrated up to a max of 2 mg/day Max dose 240 mg/day NA NA NA NA 6 Short Other (laboratory

412. Cannabis-2023-Surv-Rep-4-Tables-E-1-E-4 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2023-surv-rep-4-tables-E-1-E-4.xlsx
     January 01, 2023 - to nabilone 250 ug titrated up to a max of 2 mg/day Max dose 240 mg/day NA NA NA NA 6 Short Other (laboratory

413. Cannabis-2022-Surv-Rep-4-Tables-F1-4 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2022-surv-rep-4-tables-F1-4.xlsx
     January 01, 2022 - to nabilone 250 ug titrated up to a max of 2 mg/day Max dose 240 mg/day NA NA NA NA 6 Short Other (laboratory

414. Bladder-Cancer-Non-Muscle-Invasive Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/bladder-cancer-non-muscle-invasive_executive.pdf
     October 01, 2015 - diagnosis of bladder cancer approved by the FDA or available in the United States and classified as a Laboratory

415. Horizon Scanning_Rapid Cost Analyses of Selected Potential High-Impact Intervention Reports (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/horizon-scan_research-2015.pdf
     January 01, 2015 - sophisticated, costly infrastructure in the form of hybrid operating rooms or hybrid catheterization laboratories

416. Disposition of Comments for Technical Brief 20 Core Functionality in Pediatric Electronic Health Records (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/pediatric-ehr_disposition-comments.pdf
     May 01, 2015 - We have reworded the paragraph to emphasize the importance of laboratory data with interpretation displayed

417. Cer-250-Cannabis-2024-Surv-Rep-Update-Tables-E1-4 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2024-surv-rep-update-tables-e1-4.xlsx
     January 01, 2024 - to nabilone 250 ug titrated up to a max of 2 mg/day Max dose 240 mg/day NA NA NA NA 6 Short Other (laboratory

418. Breast-Cancer-Imaging Technical-Brief (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/breast-cancer-imaging_technical-brief.pdf
     October 01, 2014 - abdomen, and bone in addition to obtaining medical histories, physical examinations, and relevant laboratory

419. Cer-250-Cannabis-2025-Surv-Rep-Update-Tables-E1-4 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2025-surv-rep-update-tables-e1-4.xlsx
     January 01, 2025 - to nabilone 250 ug titrated up to a max of 2 mg/day Max dose 240 mg/day NA NA NA NA 6 Short Other (laboratory

420. Gestational-Diabetes-Screening-Diagnosis Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/gestational-diabetes-screening-diagnosis_executive.pdf
     October 01, 2012 - These criteria reflect changes that have occurred in laboratory glucose measurements over the years